{"id":815886,"date":"2025-02-20T16:18:20","date_gmt":"2025-02-20T21:18:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/"},"modified":"2025-02-20T16:18:20","modified_gmt":"2025-02-20T21:18:20","slug":"cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/","title":{"rendered":"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update"},"content":{"rendered":"

\n– Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET\/1:30 p.m. PT –
\n<\/h2>\n
\n

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024.<\/p>\n

\n Conference Call and Webcast<\/strong>\n <\/p>\n

Cardiff Oncology will host a conference call and live webcast at\u00a04:30 p.m. ET\/1:30 p.m. PT\u00a0on\u00a0February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at\u00a0https:\/\/investors.cardiffoncology.com\/news-events\/events<\/a>. A replay will be available in the investor relations section on the company’s website following the completion of the call.<\/p>\n

\n About Cardiff Oncology, Inc.<\/strong>\n <\/p>\n

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company’s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company’s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https:\/\/www.cardiffoncology.com<\/a>.<\/p>\n

\n Cardiff Oncology Contact:\u00a0
<\/strong>James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com<\/a><\/p>\n

\n Investor Contact:
<\/strong>Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com<\/a><\/p>\n

\n Media Contact:
<\/strong>Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET\/1:30 p.m. PT – SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at\u00a04:30 p.m. ET\/1:30 p.m. PT\u00a0on\u00a0February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of … <\/p>\n

Continue reading “Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815886","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET\/1:30 p.m. PT – SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at\u00a04:30 p.m. ET\/1:30 p.m. PT\u00a0on\u00a0February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of … Continue reading "Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T21:18:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update\",\"datePublished\":\"2025-02-20T21:18:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/\"},\"wordCount\":315,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/\",\"name\":\"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=\",\"datePublished\":\"2025-02-20T21:18:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Market Newsdesk","og_description":"– Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET\/1:30 p.m. PT – SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at\u00a04:30 p.m. ET\/1:30 p.m. PT\u00a0on\u00a0February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of … Continue reading \"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T21:18:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update","datePublished":"2025-02-20T21:18:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/"},"wordCount":315,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/","name":"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=","datePublished":"2025-02-20T21:18:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTk4MCM2NzYxMTQ1IzIyNTc1MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-report-fourth-quarter-2024-results-and-provide-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815886"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}